NEOGEN CORP SEC Filings

Neogen Corporation operates two main segments—Food Safety and Animal Safety—providing diagnostic tests, software, veterinary pharmaceuticals, biologics, rodent and insect control, and genomics services to global food producers, laboratories, and animal health markets. For the year ended May 31, 2026, 51.2% of revenue came from customers outside the U.S., and the company employed 2,636 people worldwide. Shares outstanding were 218,056,016 on June 30, 2026.

The company is integrating the 3M Food Safety Division after a 2022 Reverse Morris Trust transaction and plans a multi‑quarter transition of Petrifilm manufacturing to its Lansing site, with substantial completion expected in fiscal 2027 while incurring duplicative costs. Neogen also divested its global Cleaners and Disinfectants business in July 2025 and has agreed to sell its Genomics business to Zoetis Inc. for $160.0 million, subject to regulatory approvals including second‑phase reviews by Australian and New Zealand competition regulators.

Neogen highlights extensive intellectual property (approximately 157 U.S. patents and 445 foreign patents), ongoing R&D investment targeted at 2%–5% of revenue, and significant manufacturing and sales infrastructure across North America, Europe, Latin America and Asia Pacific. Key risks include successful completion of the Petrifilm transition and realization of 3M synergies, international trade and geopolitical exposure, data privacy and cybersecurity threats, ERP harmonization and AI-related risks, supply chain dependence, substantial indebtedness, and exposure to litigation and regulatory scrutiny.

Neogen Corporation reported Q4 FY2026 revenue of $225.3 million, essentially flat year over year with core growth of 4.3%. Food Safety revenue rose to $166.8 million, up 3.1% with 5.8% core growth, while Animal Safety declined to $58.5 million, down 8.2% with 0.5% core growth. Q4 gross margin improved to 47.8% (adjusted 49.7%), and the company posted a net loss of $11.3 million, or $(0.05) per share, compared to a net loss of $612.2 million a year earlier; adjusted net income was $18.7 million, or $0.09 per share. Adjusted EBITDA was $45.4 million, a 20.2% margin.

For FY2026, revenue was $870.4 million, down 2.7%, with adjusted EBITDA of $177.8 million and net loss of $7.9 million versus $1,092.0 million in FY2025. Cash from operations reached $83.2 million and free cash flow $31.9 million, ending the year with $185.5 million of cash and $793.7 million of debt. Neogen continues to work toward completing the previously announced sale of its global Genomics business to Zoetis for anticipated proceeds of $160 million (approximately $140 million net) to be used primarily for debt reduction, and plans to begin transitioning Petrifilm manufacturing to its Lansing site in November 2026. FY2027 guidance calls for revenue of $880–$885 million and adjusted EBITDA of $180–$182 million, including contributions from the Genomics division.

NEOGEN CORP Schedule 13G filed reporting that Neuberger Berman Group LLC and affiliated filers beneficially own 16,570,795 shares of Common Stock as of 06/30/2026, representing 7.6% of the class. The filing shows shared voting power of 15,163,045 and shared dispositive power of 16,570,795 across Neuberger Berman entities.

The filing explains holdings arise from client and fiduciary accounts aggregated under Rule 13d-3 and that the reporting entities disclaim economic ownership under Rule 13d-4; it lists Neuberger Berman Investment Advisers LLC and related trusts as part of the aggregated position.

NEOGEN CORP Chief Accounting Officer handles RSU tax withholding. On June 3, 2026, restricted stock units vested on the anniversary of the grant date. To cover taxes on the vested shares, 2,553 shares were withheld at an indicated value of $8.75 per share. After this non‑market, tax-withholding disposition, John Patrick Moylan directly holds 23,571 shares of NEOGEN stock.

Amy M. Rocklin reported the sale of 87,681 shares of common stock. The sale occurred on 05/29/2026 for proceeds of $805,153.08. The filing also lists an option granted date of 06/02/2025 and multiple administrative dates of 06/03/2026.

NEOGEN CORP’s former Chief Legal Officer, Amy M. Rocklin, exercised equity awards and settled related taxes. She converted 35,183 Restricted Stock Units into 35,183 shares of Common Stock at $9.29 per share.

To cover tax obligations, 10,241 shares of Common Stock were delivered back at $9.29 per share in a tax-withholding disposition, a non-market transaction. After these events, she directly holds 82,182 shares of NEOGEN CORP Common Stock.

Neogen Corporation Schedule 13G/A (Amendment No. 2): A group led by Clarkston Capital Partners, LLC reports beneficial ownership of 2,204,788 shares of Neogen common stock, equal to 1.01% of the class based on 217,673,041 shares outstanding as of February 28, 2026. The filing attributes 1,000,000 shares to sole voting power and 1,204,788 shares to shared dispositive power across the reporting persons. The statement is filed jointly by CCP, Clarkston Companies, Inc., and reporting individuals Jeffrey A. Hakala and Gerald W. Hakala.

NEOGEN CORP Chief Accounting Officer John Patrick Moylan reported routine equity compensation activity involving company stock. On May 4, 2026, he exercised 4,558 Restricted Stock Units into common shares at $9.53 per share. To cover related tax obligations, 1,568 common shares were disposed of as a tax-withholding transaction, not an open-market sale. Following these transactions, Moylan directly holds 17,337 shares of NEOGEN common stock.